{"transactions":[{"id":690675,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock","published_at":"2026-08-11T20:21:36.000Z","date":"2026-08-08","kind":"exercise","planned":false,"acquired":false,"shares":1600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Distribution of time-based service award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Distribution of time-based service award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025."}],"balance_after":19624,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1600},"source":{"system":"sec-edgar","filing":"0000897069-26-001602","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001602/form4.xml","form_type":"4"}},{"id":690674,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-11T20:21:36.000Z","date":"2026-08-08","kind":"exercise","planned":false,"acquired":true,"shares":1600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of time-based service award."}],"balance_after":17092,"source":{"system":"sec-edgar","filing":"0000897069-26-001602","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001602/form4.xml","form_type":"4"}},{"id":702185,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-29T00:26:33.000Z","date":"2026-07-26","kind":"grant","planned":false,"acquired":true,"shares":9384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025."}],"balance_after":21224,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":9384},"source":{"system":"sec-edgar","filing":"0000897069-26-001554","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001554/form4.xml","form_type":"4"}},{"id":721192,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:19:02.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3057,"price":1.93,"value":5900.01,"ownership":{"direct":true},"balance_after":15492,"source":{"system":"sec-edgar","filing":"0000897069-26-001480","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001480/form4.xml","form_type":"4"}},{"id":736141,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-16T20:22:10.000Z","date":"2026-06-15","kind":"purchase","planned":false,"acquired":true,"shares":2465,"price":2.22,"value":5472.3,"ownership":{"direct":true},"balance_after":12435,"source":{"system":"sec-edgar","filing":"0000897069-26-001410","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001410/form4.xml","form_type":"4"}},{"id":757041,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-01T20:58:18.000Z","date":"2026-05-29","kind":"purchase","planned":false,"acquired":true,"shares":2129,"price":2.57,"value":5471.53,"ownership":{"direct":true},"balance_after":9970,"source":{"system":"sec-edgar","filing":"0000897069-26-001291","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001291/form4.xml","form_type":"4"}},{"id":772009,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-19T22:06:01.000Z","date":"2026-05-15","kind":"purchase","planned":false,"acquired":true,"shares":1843,"price":2.97,"value":5473.71,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 15 shares."}],"balance_after":7841,"source":{"system":"sec-edgar","filing":"0000897069-26-001186","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001186/form4.xml","form_type":"4"}},{"id":772008,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-19T21:31:29.000Z","date":"2026-04-15","kind":"purchase","planned":false,"acquired":true,"shares":1843,"price":2.97,"value":5473.71,"ownership":{"direct":true},"balance_after":3979,"source":{"system":"sec-edgar","filing":"0000897069-26-001167","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001167/form4a.xml","form_type":"4/A","original_submission_date":"2026-04-17"}},{"id":795605,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-01T20:37:24.000Z","date":"2026-04-30","kind":"purchase","planned":false,"acquired":true,"shares":2034,"price":2.69,"value":5471.46,"ownership":{"direct":true},"balance_after":6013,"source":{"system":"sec-edgar","filing":"0000897069-26-001006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926001006/form4.xml","form_type":"4"}},{"id":796828,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-30T20:33:51.000Z","date":"2026-04-15","kind":"purchase","planned":false,"acquired":true,"shares":1843,"price":2.97,"value":5473.71,"ownership":{"direct":true},"balance_after":3979,"source":{"system":"sec-edgar","filing":"0000897069-26-000979","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926000979/form4a.xml","form_type":"4/A","original_submission_date":"2026-04-17"}},{"id":796827,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-30T20:32:54.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":2136,"price":2.535,"value":5414.76,"ownership":{"direct":true},"balance_after":2136,"source":{"system":"sec-edgar","filing":"0000897069-26-000977","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926000977/form4a.xml","form_type":"4/A","original_submission_date":"2026-04-01"}},{"id":805611,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-17T20:54:02.000Z","date":"2026-04-15","kind":"purchase","planned":false,"acquired":true,"shares":1843,"price":2.97,"value":5473.71,"ownership":{"direct":true},"balance_after":5492,"source":{"system":"sec-edgar","filing":"0000897069-26-000910","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926000910/form4.xml","form_type":"4"}},{"id":822838,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-01T21:15:37.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":2136,"price":2.535,"value":5414.76,"ownership":{"direct":true},"balance_after":3649,"source":{"system":"sec-edgar","filing":"0000897069-26-000750","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926000750/form4.xml","form_type":"4"}},{"id":900978,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2026-02-17T21:19:47.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":156240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."}],"balance_after":156240,"derivative":{"exercise_price":1.29,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":156240},"source":{"system":"sec-edgar","filing":"0000897069-26-000367","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926000367/form4.xml","form_type":"4"}},{"id":1024519,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-10-03T20:23:59.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":768000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years."}],"balance_after":768000,"derivative":{"exercise_price":0.198,"underlying":"Common Stock","underlying_shares":768000},"source":{"system":"sec-edgar","filing":"0000897069-25-001543","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706925001543/form4.xml","form_type":"4"}},{"id":1024518,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-03T20:23:59.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":256000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028."}],"balance_after":256000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":256000},"source":{"system":"sec-edgar","filing":"0000897069-25-001543","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706925001543/form4.xml","form_type":"4"}},{"id":1080589,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-28T20:25:47.000Z","date":"2025-07-24","kind":"grant","planned":false,"acquired":true,"shares":1822471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan (\"Omnibus Plan\"), of which 1,859,318 shares are subject to stockholder approval of the revised Omnibus Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028."}],"balance_after":1922471,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1822471},"source":{"system":"sec-edgar","filing":"0000897069-25-001213","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706925001213/form4.xml","form_type":"4"}},{"id":1263769,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Warrants","published_at":"2025-02-18T22:53:15.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":43600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"George Ng IRRA FBO: George Ng"},"balance_after":43600,"derivative":{"exercise_price":0.65,"exercise_date":"2025-01-29","expiration_date":"2030-01-29","underlying":"Common Stock","underlying_shares":43600},"source":{"system":"sec-edgar","filing":"0000897069-25-000290","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706925000290/form4.xml","form_type":"4/A","original_submission_date":"2025-01-29"}},{"id":1263768,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Warrants","published_at":"2025-02-18T22:53:15.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":87200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"George Ng IRRA FBO: George Ng"},"balance_after":87200,"derivative":{"exercise_price":0.65,"exercise_date":"2025-01-29","expiration_date":"2030-01-29","underlying":"Common Stock","underlying_shares":87200},"source":{"system":"sec-edgar","filing":"0000897069-25-000290","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706925000290/form4.xml","form_type":"4/A","original_submission_date":"2025-01-29"}},{"id":1291800,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-29T22:05:00.000Z","date":"2025-01-27","kind":"purchase","planned":false,"acquired":true,"shares":87200,"price":0.7975,"value":69542.0,"ownership":{"direct":false,"nature":"George Ng IRRA FBO: George Ng"},"balance_after":87200,"source":{"system":"sec-edgar","filing":"0000897069-25-000134","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706925000134/form4.xml","form_type":"4"}},{"id":1310637,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2025-01-06T21:54:16.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":51275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."}],"balance_after":51275,"derivative":{"exercise_price":4.11,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":51275},"source":{"system":"sec-edgar","filing":"0000897069-25-000031","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706925000031/form4.xml","form_type":"4"}},{"id":1382913,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:47:13.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":13553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":13553,"derivative":{"exercise_price":4.14,"exercise_date":"2024-10-18","expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":13553},"source":{"system":"sec-edgar","filing":"0000897069-24-002011","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706924002011/form4.xml","form_type":"4"}},{"id":1382912,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:47:13.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":13553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":13553,"derivative":{"exercise_price":3.69,"exercise_date":"2024-10-18","expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":13553},"source":{"system":"sec-edgar","filing":"0000897069-24-002011","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706924002011/form4.xml","form_type":"4"}},{"id":1382911,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:47:13.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":35780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":35780,"derivative":{"exercise_price":2.24,"exercise_date":"2024-10-18","expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":35780},"source":{"system":"sec-edgar","filing":"0000897069-24-002011","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706924002011/form4.xml","form_type":"4"}},{"id":1665164,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-31T21:37:40.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.7,"value":27000.0,"ownership":{"direct":false,"nature":"By Family Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects that shares previously reported as directly held by the reporting person were held in a trust."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000897069-24-000229","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706924000229/form4.xml","form_type":"4"}},{"id":1761153,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-12T22:04:18.000Z","date":"2023-10-12","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0.25,"value":25000.0,"ownership":{"direct":true},"balance_after":200000,"source":{"system":"sec-edgar","filing":"0000897069-23-001468","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706923001468/form4.xml","form_type":"4"}},{"id":1762571,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-10T20:56:17.000Z","date":"2023-10-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0.25,"value":25000.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000897069-23-001438","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706923001438/form4.xml","form_type":"4"}},{"id":1811982,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-09T20:51:20.000Z","date":"2023-08-08","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest upon the achievement of certain performance goals."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest upon the achievement of certain performance goals."}],"balance_after":800000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000897069-23-001136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706923001136/form4.xml","form_type":"4"}},{"id":1811981,"issuer":{"id":8210,"kind":"organization","name":"Processa Pharmaceuticals, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-09T20:51:20.000Z","date":"2023-08-08","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting of one-third on 08/08/24, 08/08/25, and 08/08/26 or upon a change in control event."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting of one-third on 08/08/24, 08/08/25, and 08/08/26 or upon a change in control event."}],"balance_after":400000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000897069-23-001136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706923001136/form4.xml","form_type":"4"}},{"id":4028669,"issuer":{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-02-28T19:04:44.000Z","date":"2018-02-28","kind":"purchase","acquired":true,"shares":90000,"price":9.95,"value":895500.0,"ownership":{"direct":false,"nature":"By Ng Cha Family Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held in a family trust of which the Reporting Person is a co-trustee with his wife."}],"balance_after":101453,"source":{"system":"sec-edgar","filing":"0000850261-18-000010","document":"wf-form4_151986267025828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/850261/000085026118000010/wf-form4_151986267025828.xml","form_type":"4"}},{"id":4028668,"issuer":{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-02-28T19:04:44.000Z","date":"2018-02-28","kind":"other","acquired":true,"shares":163469,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a stock purchase agreement by and among the Issuer, Scilex Pharmaceuticals Inc. (\"Scilex\"), the stockholders of Scilex party thereto and SPI Shareholders Representative, LLC, as representative of the Scilex Stockholders (the \"Stock Purchase Agreement\"), the Reporting Person sold 1,800,000 shares of common stock of Scilex to the Issuer and, upon the achievement of a milestone on February 28, 2018, the Issuer issued the Reporting Person 163,469 shares of the common stock of the Issuer. The Stock Purchase Agreement, which was entered into on November 8, 2016, placed a value on the Issuer's common stock of $9.95 per share. Contingent upon the achievement of such milestone, the Reporting Person's right to receive such shares became fixed and irrevocable on November 8, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a stock purchase agreement by and among the Issuer, Scilex Pharmaceuticals Inc. (\"Scilex\"), the stockholders of Scilex party thereto and SPI Shareholders Representative, LLC, as representative of the Scilex Stockholders (the \"Stock Purchase Agreement\"), the Reporting Person sold 1,800,000 shares of common stock of Scilex to the Issuer and, upon the achievement of a milestone on February 28, 2018, the Issuer issued the Reporting Person 163,469 shares of the common stock of the Issuer. The Stock Purchase Agreement, which was entered into on November 8, 2016, placed a value on the Issuer's common stock of $9.95 per share. Contingent upon the achievement of such milestone, the Reporting Person's right to receive such shares became fixed and irrevocable on November 8, 2016."}],"balance_after":302146,"source":{"system":"sec-edgar","filing":"0000850261-18-000010","document":"wf-form4_151986267025828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000085026118000010/wf-form4_151986267025828.xml","form_type":"4"}},{"id":4208819,"issuer":{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Options","published_at":"2017-09-15T21:46:11.000Z","date":"2017-09-14","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the original number of shares subject to the option shall vest on September 14, 2018 and 1/48 of the original number of shares subject to the option shall vest following each one month period of service after September 14, 2018, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":150000,"derivative":{"exercise_price":1.8,"expiration_date":"2027-09-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001144204-17-048362","document":"v475328_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000114420417048362/v475328_4.xml","form_type":"4"}},{"id":4208811,"issuer":{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-09-15T21:26:40.000Z","date":"2017-09-11","kind":"other","acquired":true,"shares":89339,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a stock purchase agreement by and among the Issuer, Scilex Pharmaceuticals Inc. (\"Scilex\"), the stockholders of Scilex party thereto and SPI Shareholders Representative, LLC, as representative of the Scilex Stockholders (the \"Stock Purchase Agreement\"), the Reporting Person sold 1,800,000 shares of common stock of Scilex to the Issuer and, upon the achievement of a milestone on September 11, 2017, the Issuer issued the Reporting Person 89,339 shares of the common stock of the Issuer. The Stock Purchase Agreement, which was entered into on November 8, 2016, placed a value on the Issuer's common stock of $6.33 per share. Contingent upon the achievement of such milestone, the Reporting Person's right to receive such shares became fixed and irrevocable on November 8, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a stock purchase agreement by and among the Issuer, Scilex Pharmaceuticals Inc. (\"Scilex\"), the stockholders of Scilex party thereto and SPI Shareholders Representative, LLC, as representative of the Scilex Stockholders (the \"Stock Purchase Agreement\"), the Reporting Person sold 1,800,000 shares of common stock of Scilex to the Issuer and, upon the achievement of a milestone on September 11, 2017, the Issuer issued the Reporting Person 89,339 shares of the common stock of the Issuer. The Stock Purchase Agreement, which was entered into on November 8, 2016, placed a value on the Issuer's common stock of $6.33 per share. Contingent upon the achievement of such milestone, the Reporting Person's right to receive such shares became fixed and irrevocable on November 8, 2016."}],"balance_after":138677,"source":{"system":"sec-edgar","filing":"0001144204-17-048347","document":"v475331_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000114420417048347/v475331_4.xml","form_type":"4"}},{"id":4469964,"issuer":{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-02-03T19:46:02.000Z","date":"2017-02-03","kind":"sale","acquired":false,"shares":40000,"price":5.15,"value":206000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's sale of 40,000 shares of common stock of the Issuer reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 40,000 shares, with the Reporting Person's receipt of 89,338 shares of common stock of the Issuer in exchange for 1,800,000 shares of common stock of Scilex Pharmaceuticals Inc. (\"Scilex\") on November 8, 2016 pursuant to a stock purchase agreement by and among the Issuer, Scilex, the stockholders of Scilex party thereto (the \"Scilex Stockholders\") and SPI Shareholders Representative, LLC, as representative of the Scilex Stockholders (the \"Stock Purchase Agreement\").  The Stock Purchase Agreement placed a value on the Issuer's common stock of $6.33 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) These transactions did not result in short-swing profits, as the price per share of the shares received by the Reporting Person pursuant to the Stock Purchase Agreement exceeded the price per share of the shares sold. In the event these transactions were determined to have resulted in short-swing profits, the Reporting Person has agreed to pay to the Issuer the full amount of any profit realized in connection with the transaction, less transaction costs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The total number of shares reported as directly beneficially owned by the Reporting Person has been reduced by 888 shares due to prior over-reporting of such shares as being directly beneficially owned by the Reporting Person."}],"balance_after":49338,"source":{"system":"sec-edgar","filing":"0000899243-17-002781","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924317002781/doc4.xml","form_type":"4"}},{"id":4562982,"issuer":{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc."},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2016-11-09T20:29:35.000Z","date":"2016-11-08","kind":"grant","acquired":true,"shares":89338,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a stock purchase agreement by and among the Issuer, Scilex Pharmaceuticals Inc. (\"Scilex\"), the stockholders of Scilex party thereto (the \"Scilex Stockholders\") and SPI Shareholders Representative, LLC, as representative of the Scilex Stockholders (the \"Stock Purchase Agreement\"), the Reporting Person sold 1,800,000 shares of common stock of Scilex to the Issuer in exchange for 89,338 shares of common stock of the Issuer.  The Stock Purchase Agreement, which was entered into on November 8, 2016, placed a value on the Issuer's common stock of $6.33 per share. Of the 89,338 shares issued to the Reporting Person pursuant to the Stock Purchase Agreement, 17,867 are currently being held in escrow and are subject to forfeiture until May 8, 2017 to satisfy claims arising as a result of Scilex's or the Reporting Person's breach of their representations, warranties or covenants contained in the Stock Purchase Agreement."}],"balance_after":90226,"source":{"system":"sec-edgar","filing":"0000899243-16-033098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924316033098/doc4.xml","form_type":"4"}}]}